NCT06441669View on ClinicalTrials.gov

Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT

RecruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

May 1, 2026

Study Completion Date

May 20, 2026

Conditions
Cytomegalovirus Infection Reactivation
Interventions
DRUG

Letermovir

Patients will be given Letermovir with a recommended dose from +1 day to +100 days after UCBT.

Trial Locations (1)

Unknown

RECRUITING

Anhui Provincial Hospital, Hefei

All Listed Sponsors
lead

Anhui Provincial Hospital

OTHER_GOV